Streetbeat News

Earnings

UNH

The article compares UnitedHealth Group (UNH) with its competitors in the Health Care Providers & Services industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. UnitedHealth shows potential value with a lower P/E ratio, but its P/B ratio suggests overvaluation. Its low P/S ratio indicates undervaluation based on sales, while a negative ROE and lower revenue growth highlight challenges. The company's high EBITDA and gross profit suggest strong profitability.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 3:00 pm

AVGO

Broadcom (NASDAQ:AVGO) is analyzed alongside competitors in the Semiconductors & Semiconductor Equipment industry, highlighting its financial performance and market positioning. Despite a lower PE ratio suggesting potential undervaluation, Broadcom's high PB and PS ratios may indicate overvaluation. Its ROE is below the industry average, suggesting inefficiency in utilizing equity. However, Broadcom's EBITDA, gross profit, and revenue growth are significantly above the industry average, indicating strong operational performance and growth potential.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 3:00 pm

PCAR

PACCAR Inc. projects its capital expenditures to be between $700M-$750M and its research and development expenses to be between $460M-$500M for the year 2024, as stated by Harrie Schippers, PACCAR's President and CFO.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 2:54 pm

BLND

LLY

WGS

Eli Lilly raised its FY24 revenue guidance, leading to a 6.6% surge in its shares. Other companies like GeneDx Holdings, Blend Labs, and LendingTree also reported positive financial results or strategic moves, contributing to significant stock gains. Notable mentions include Harmonic Inc., ATI Inc., and Clearwater Paper Corporation, among others, all experiencing stock price increases following upbeat quarterly results or guidance updates.

Portfolio Pulse from Avi Kapoor

April 30, 2024 | 2:53 pm

THC

Tenet Healthcare Corporation (NYSE:THC) reported first-quarter sales of $5.37 billion, a 7% increase year over year, surpassing the consensus of $5.15 billion. Adjusted EBITDA for Q1 2024 was $1.024 billion, up from $832 million the previous year, driven by strong admission growth, favorable payer mix, and improved contract labor costs. The company raised its fiscal year 2024 revenue guidance to $20 billion-$20.4 billion and adjusted EPS guidance to $8.37-$9.41, significantly above the consensus of $6.11. Shares of THC surged 9.97% to $109.08.

Portfolio Pulse from Vandana Singh

April 30, 2024 | 2:53 pm

LLY

Eli Lilly expects acceleration and revenue growth through H2 2024 due to increased supply of incretin medicines. The company is investing to expand capacity for these medicines. Additionally, Eli Lilly anticipates CMS and Medicare coverage for Zepbound, its obstructive sleep apnea treatment, at launch.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 2:47 pm

SYY

During a conference call, a Sysco Corp executive mentioned that while food costs have seen moderation, labor costs at restaurants continue to remain high.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 2:45 pm

PCAR

PACCAR shares are trading lower following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 2:40 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) has seen significant options activity, with over 16 transactions valued at $427,360, focusing on a price band between $880.0 and $905.0. The stock's current price is $894.58, with a 0.24% increase and an RSI indicating it may be approaching oversold territory. Analyst ratings in the last 30 days have set an average price target of $1033.6, with varying recommendations from Buy to Neutral. The next earnings report is expected in 2 days.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 2:31 pm

MUSQ

SIRI

UFO

Sirius XM Holdings Inc (NASDAQ: SIRI) reported a slight revenue growth in Q1 2024, with a 1% increase year-on-year to $2.16 billion, surpassing consensus estimates. Despite a dip in subscriber numbers, advertising revenue saw significant growth. The company's adjusted EPS met expectations, and it reiterated its FY24 outlook, maintaining revenue and adjusted EBITDA forecasts. Sirius XM's stock has seen a decline over the past year, with a notable 5.3% drop recently. The company is also featured in the Procure Space ETF (NASDAQ: UFO) and Exchange Traded Concepts Trust MUSQ Global Music Industry ETF (NYSE: MUSQ).

Portfolio Pulse from Anusuya Lahiri

April 30, 2024 | 2:30 pm